Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
780.60
Change Change %
-2.50 -0.32%

Updated:15 Nov, 2018, 15:59 PM IST

BSE
780.20
Change Change %
-2.50 -0.32%

Updated:15 Nov, 2018, 16:01 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Religare
N/A
11-02-2016 Buy 671.55 1000.00
N/A
Closed Custom
11-02-2017

Religare maintains buy on Aurobindo Pharma

Aurobindo's topline grew 10.4 per cent year-on-year to Rs 3,490 crore on robust US sales led by ramp-up in recent launches. However, net profit was below expectation due to lower other income. Revise FY17/FY18 revenue estimates by 5.5 and 4.4 per cent respectively building in lower sales and slow European Union business recovery.

Top